PET-guided dose escalation tomotherapy in malignant pleural mesothelioma

Andrei Fodor, Claudio Fiorino, Italo Dell'Oca, Sara Broggi, Marcella Pasetti, Giovanni Mauro Cattaneo, Luigi Gianolli, Riccardo Calandrino, Nadia Gisella Di Muzio

Research output: Contribution to journalArticle

Abstract

Purpose: To test the feasibility of salvage radiotherapy using PET-guided helical tomotherapy in patients with progressive malignant pleural mesothelioma (MPM). Patients and Methods: A group of 12 consecutive MPM patients was treated with 56 Gy/25 fractions to the planning target volume (PTV); FDG-PET/CT simulation was always performed to include all positive lymph nodes and MPM infiltrations. Subsequently, a second group of 12 consecutive patients was treated with the same dose to the whole pleura adding a simultaneous integrated boost of 62.5 Gy to the FDG-PET/CT positive areas (BTV). Results: Good dosimetric results were obtained in both groups. No grade 3 (RTOG/EORTC) acute or late toxicities were reported in the first group, while 3 cases of grade 3 late pneumonitis were registered in the second group: the duration of symptoms was 2-10 weeks. Median overall survival was 8 months (1.2-50.5 months) and 20 months (4.3-33.8 months) from the beginning of radiotherapy, for groups I and II, respectively (p = 0.19). A significant impact on local relapse from radiotherapy was seen (median time to local relapse: 8 vs 17 months; 1-year local relapse-free rate: 16% vs 81%, p = 0.003). Conclusions: The results of this pilot study support the planning of a phase III study of combined sequential chemoradiotherapy with dose escalation to BTV in patients not able to undergo resection.

Original languageEnglish
Pages (from-to)736-743
Number of pages8
JournalStrahlentherapie und Onkologie
Volume187
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Radiotherapy
Recurrence
Intensity-Modulated Radiotherapy
Pleura
Chemoradiotherapy
Pneumonia
Lymph Nodes
Malignant Mesothelioma
Survival

Keywords

  • Helical tomotherapy
  • IGRT
  • Malignant pleural mesothelioma
  • PET imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. / Fodor, Andrei; Fiorino, Claudio; Dell'Oca, Italo; Broggi, Sara; Pasetti, Marcella; Cattaneo, Giovanni Mauro; Gianolli, Luigi; Calandrino, Riccardo; Di Muzio, Nadia Gisella.

In: Strahlentherapie und Onkologie, Vol. 187, No. 11, 11.2011, p. 736-743.

Research output: Contribution to journalArticle

Fodor, Andrei ; Fiorino, Claudio ; Dell'Oca, Italo ; Broggi, Sara ; Pasetti, Marcella ; Cattaneo, Giovanni Mauro ; Gianolli, Luigi ; Calandrino, Riccardo ; Di Muzio, Nadia Gisella. / PET-guided dose escalation tomotherapy in malignant pleural mesothelioma. In: Strahlentherapie und Onkologie. 2011 ; Vol. 187, No. 11. pp. 736-743.
@article{70f7f4da8a31499d8e99079f24edd0a2,
title = "PET-guided dose escalation tomotherapy in malignant pleural mesothelioma",
abstract = "Purpose: To test the feasibility of salvage radiotherapy using PET-guided helical tomotherapy in patients with progressive malignant pleural mesothelioma (MPM). Patients and Methods: A group of 12 consecutive MPM patients was treated with 56 Gy/25 fractions to the planning target volume (PTV); FDG-PET/CT simulation was always performed to include all positive lymph nodes and MPM infiltrations. Subsequently, a second group of 12 consecutive patients was treated with the same dose to the whole pleura adding a simultaneous integrated boost of 62.5 Gy to the FDG-PET/CT positive areas (BTV). Results: Good dosimetric results were obtained in both groups. No grade 3 (RTOG/EORTC) acute or late toxicities were reported in the first group, while 3 cases of grade 3 late pneumonitis were registered in the second group: the duration of symptoms was 2-10 weeks. Median overall survival was 8 months (1.2-50.5 months) and 20 months (4.3-33.8 months) from the beginning of radiotherapy, for groups I and II, respectively (p = 0.19). A significant impact on local relapse from radiotherapy was seen (median time to local relapse: 8 vs 17 months; 1-year local relapse-free rate: 16{\%} vs 81{\%}, p = 0.003). Conclusions: The results of this pilot study support the planning of a phase III study of combined sequential chemoradiotherapy with dose escalation to BTV in patients not able to undergo resection.",
keywords = "Helical tomotherapy, IGRT, Malignant pleural mesothelioma, PET imaging",
author = "Andrei Fodor and Claudio Fiorino and Italo Dell'Oca and Sara Broggi and Marcella Pasetti and Cattaneo, {Giovanni Mauro} and Luigi Gianolli and Riccardo Calandrino and {Di Muzio}, {Nadia Gisella}",
year = "2011",
month = "11",
doi = "10.1007/s00066-011-2234-6",
language = "English",
volume = "187",
pages = "736--743",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "11",

}

TY - JOUR

T1 - PET-guided dose escalation tomotherapy in malignant pleural mesothelioma

AU - Fodor, Andrei

AU - Fiorino, Claudio

AU - Dell'Oca, Italo

AU - Broggi, Sara

AU - Pasetti, Marcella

AU - Cattaneo, Giovanni Mauro

AU - Gianolli, Luigi

AU - Calandrino, Riccardo

AU - Di Muzio, Nadia Gisella

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To test the feasibility of salvage radiotherapy using PET-guided helical tomotherapy in patients with progressive malignant pleural mesothelioma (MPM). Patients and Methods: A group of 12 consecutive MPM patients was treated with 56 Gy/25 fractions to the planning target volume (PTV); FDG-PET/CT simulation was always performed to include all positive lymph nodes and MPM infiltrations. Subsequently, a second group of 12 consecutive patients was treated with the same dose to the whole pleura adding a simultaneous integrated boost of 62.5 Gy to the FDG-PET/CT positive areas (BTV). Results: Good dosimetric results were obtained in both groups. No grade 3 (RTOG/EORTC) acute or late toxicities were reported in the first group, while 3 cases of grade 3 late pneumonitis were registered in the second group: the duration of symptoms was 2-10 weeks. Median overall survival was 8 months (1.2-50.5 months) and 20 months (4.3-33.8 months) from the beginning of radiotherapy, for groups I and II, respectively (p = 0.19). A significant impact on local relapse from radiotherapy was seen (median time to local relapse: 8 vs 17 months; 1-year local relapse-free rate: 16% vs 81%, p = 0.003). Conclusions: The results of this pilot study support the planning of a phase III study of combined sequential chemoradiotherapy with dose escalation to BTV in patients not able to undergo resection.

AB - Purpose: To test the feasibility of salvage radiotherapy using PET-guided helical tomotherapy in patients with progressive malignant pleural mesothelioma (MPM). Patients and Methods: A group of 12 consecutive MPM patients was treated with 56 Gy/25 fractions to the planning target volume (PTV); FDG-PET/CT simulation was always performed to include all positive lymph nodes and MPM infiltrations. Subsequently, a second group of 12 consecutive patients was treated with the same dose to the whole pleura adding a simultaneous integrated boost of 62.5 Gy to the FDG-PET/CT positive areas (BTV). Results: Good dosimetric results were obtained in both groups. No grade 3 (RTOG/EORTC) acute or late toxicities were reported in the first group, while 3 cases of grade 3 late pneumonitis were registered in the second group: the duration of symptoms was 2-10 weeks. Median overall survival was 8 months (1.2-50.5 months) and 20 months (4.3-33.8 months) from the beginning of radiotherapy, for groups I and II, respectively (p = 0.19). A significant impact on local relapse from radiotherapy was seen (median time to local relapse: 8 vs 17 months; 1-year local relapse-free rate: 16% vs 81%, p = 0.003). Conclusions: The results of this pilot study support the planning of a phase III study of combined sequential chemoradiotherapy with dose escalation to BTV in patients not able to undergo resection.

KW - Helical tomotherapy

KW - IGRT

KW - Malignant pleural mesothelioma

KW - PET imaging

UR - http://www.scopus.com/inward/record.url?scp=84856227197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856227197&partnerID=8YFLogxK

U2 - 10.1007/s00066-011-2234-6

DO - 10.1007/s00066-011-2234-6

M3 - Article

C2 - 22037650

AN - SCOPUS:84856227197

VL - 187

SP - 736

EP - 743

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 11

ER -